文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

从被动到预测:推进皮肤病学生物制剂给药优化

From reactive to predictive: Advancing biologic dosing in dermatology.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-11-14

生物制剂治疗银屑病、化脓性汗腺炎和特应性皮炎等慢性炎症性皮肤病高效安全,但标准化给药未考虑个体差异,导致部分患者药物暴露不理想。治疗药物监测(TDM)可基于血药浓度调整剂量,但阈值调整无法预测个体药代动力学变异或未来临床结局。模型引导精准给药(MIPD)整合群体药代动力学-药效学模型、患者特征和贝叶斯预测,提供个性化自适应给药建议,有望实现主动剂量调整。

要点

  • 标准化生物制剂给药未考虑个体间异质性,可能导致原发无应答、继发失效或不良反应。
  • TDM基于血药浓度阈值调整剂量,但无法预测个体药代动力学变异或未来临床结局。
  • MIPD整合群体药代动力学-药效学模型、患者特征和贝叶斯预测,实现个性化自适应给药。

核心结论

  • MIPD代表超越传统TDM的进化,通过整合群体药代动力学-药效学模型、患者特征和贝叶斯预测,提供个性化自适应给药建议。
  • MIPD一旦常规应用,有望通过动态、以患者为中心的系统改变生物制剂给药,最大化临床应答、减少过度治疗并支持可持续医疗。

研究设计与样本

  • 本文为综述,讨论生物制剂在慢性炎症性皮肤病中的给药优化策略,从TDM到MIPD的演进。

主要发现

  • 标准化给药方案未考虑个体间异质性,导致部分患者药物暴露不理想,可能部分解释原发无应答、继发失效或不良反应。
  • TDM基于血清药物浓度调整剂量以维持治疗范围,依赖已建立的剂量-暴露-应答相关性,但阈值调整无法预测个体药代动力学变异或未来临床结局。
  • MIPD整合群体药代动力学-药效学模型、患者特征和贝叶斯预测,可捕捉个体间变异并将血清药物浓度与临床应答关联,利用稀疏或非稳态数据实现主动剂量调整。
  • 新兴数字工具、即时检测以及药物基因组学和生物标志物谱整合有望增强MIPD的精准性和可及性。

临床怎么用

  • 临床中可考虑TDM进行反应性或主动性剂量优化,但需认识其阈值调整的局限性。
  • MIPD可提供个性化自适应给药建议,利用稀疏或非稳态数据实现主动剂量调整,有望最大化临床应答并减少过度治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biologic therapies are targeted immunomodulators that have revolutionised the treatment of chronic inflammatory dermatoses, including psoriasis, hidradenitis suppurativa and atopic dermatitis, offering high efficacy and safety for moderate-to-severe disease. However, standardised dosing regimens fail to account for inter-individual heterogeneity, leading to non-optimal drug exposure in certain patients. This may, in part, explain why primary non-response, secondary loss of response or adverse effects are observed in real-world practice. While empirical off-label adjustments are commonly employed, data-driven dosing optimisation may enable better disease control and reduce the burden of lifelong biologic treatment by avoiding excessive dosing. Therapeutic drug monitoring (TDM) involves adjusting doses based on serum drug concentrations to maintain therapeutic ranges, relying on established dose-exposure-response correlations. Although TDM provides reactive or proactive optimisation approaches, its threshold-based adjustments are limited by an inability to predict individual pharmacokinetic variability or future clinical outcomes. Model-informed precision dosing (MIPD) represents an evolution beyond conventional TDM by integrating population pharmacokinetic-pharmacodynamic models, patient-specific characteristics and Bayesian forecasting to deliver personalised, adaptive dosing recommendations. This approach captures inter-individual variability while linking serum drug concentrations to clinical response, enabling proactive dose adjustments using sparse or non-steady-state data. Emerging digital tools, point-of-care testing and integration of pharmacogenomics and biomarker profiling are expected to enhance MIPD's precision and accessibility. Once implemented in routine care, MIPD has the potential to transform biologic therapy dosing using a dynamic, patient-centric system that maximises clinical response, minimises overtreatment and supports sustainable healthcare delivery.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Eylenbosch A, Wei R, Soenen R, et al. From reactive to predictive: Advancing biologic dosing in dermatology. J Eur Acad Dermatol Venereol. 2025. PMID: 41235748. doi:10.1111/jdv.70147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。